Akèy › Ateroskleroz › Texas
Etid klinik pou Ateroskleroz nan Texas
11 etid pou Ateroskleroz ap chèche patisipan nan sit nan Texas.
Vil nan Texas
- Houston10 etid
- Dallas7 etid
- Amarillo6 etid
- The Woodlands6 etid
- San Antonio5 etid
- El Paso4 etid
- McAllen4 etid
- Mesquite3 etid
- McKinney3 etid
- Austin3 etid
- Fort Worth3 etid
Tèks ofisyèl etid la (Anglè)
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
- Horizon Clinical Research Group, Cypress
- Cardiovascular Specialists of Willowbrook, Houston
- Texas Cardiology Associates of Houston, Kingwood
- ak 2 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07783802A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events
- Southwest Family Medicine Associates, Dallas
- East Texas Cardiology PA, Houston
- Cardiovascular Specialists of Willowbrook, Houston
- ak 1 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07448038Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
- PharmaTex Research, Amarillo
- St. David's Heart & Vascular PLLC dba Austin Heart, Austin
- Velocity Clinical Research, Austin, Austin
- ak 18 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT07157774A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis
- PharmaTex Research, LLC, Amarillo
- Pulse Care Heart and Vascular, Carrollton
- DM Clinical Research - Dallas, Tomball
Ap rekriteFaz 2
Laj 18 a 80 · Tout sèks · Mizajou Sep 22, 2026 · NCT07521007Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- PharmaTex Research, LLC, Amarillo
- Austin Heart, Austin
- Velocity Clinical Research - Austin, Austin
- ak 22 plis
Ap rekriteFaz 3
Laj 45 a 99 · Tout sèks · Mizajou Sep 22, 2026 · NCT07037433Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
- Cussimanio Research Group LLC, Austin
- Research Management, Inc., Austin
- MW Clinical Research Center, Beaumont
- ak 22 plis
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT05485961A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
- Research Site, Amarillo
- Research Site, Beaumont
- Research Site, Brownsville
- ak 33 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 24, 2026 · NCT07000357Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
- PharmaTex Research LLC, Amarillo
- Kelsey Seybold Research Foundation, Houston
- Northwest Houston Clinical Research PLLC, Tomball
Ap rekriteFaz 3
Laj 18 a 80 · Tout sèks · Mizajou Aug 7, 2026 · NCT06813911Pelacarsen Roll-over Extension Program
- Plano Primary Care Clinic, Allen
- Pharma Tex Research, Amarillo
- SW Family Medicine Associates, Dallas
- ak 8 plis
Ap rekriteFaz 3
Laj 18 a 100 · Tout sèks · Mizajou Jul 29, 2026 · NCT06875973Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
- UT Health Houston, Houston
Ap rekriteFaz 2
Laj 40 ak plis · Tout sèks · Mizajou Dec 17, 2025 · NCT05488431Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
- VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas
- Michael E. DeBakey VA Medical Center, Houston, TX, Houston
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Dec 17, 2025 · NCT02915198Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.